乐土 is an innovative drug R&D and manufacturing company that aims to build a precision medical industry ecosystem. Its stated scope includes biologics development and manufacturing, genetic testing, innovative drug research and development, and medical and elderly-care bases. The company positions itself as an integrated platform combining biopharmaceutical development, testing, clinical R&D and care facilities. Recent reporting notes the company has progressed through multiple financing rounds. The articles do not disclose product revenues, user metrics, or detailed financials. Public coverage emphasizes the company’s ecosystem strategy rather than specific commercial results. LeTu Life Sciences operates an integrated R&D and service platform spanning biopharmaceuticals, CRO/CDMO, molecular diagnostics and medical services. The company was founded in July 2016 and has a registered capital of RMB800 million. It has built operations and project layouts in the U.S., Shenzhen, Shanghai, Beijing and Hebei. LeTu aims to become a leading Chinese biotech and a world‑class biopharma and medical technology company. The firm recently completed its first equity financing and after the round its valuation reached RMB7.2 billion. Management says proceeds will be used for new product development and for acquisitions of high‑quality projects.

Total raised

$167M

Funding rounds

2

Latest round

Series B

Latest activity

Oct 2023